Treatment Approaches for Multiple Myeloma: A Review

Citation:
W G, M O, GO O. "Treatment Approaches for Multiple Myeloma: A Review." Journal of Kenya Association of Physicians. 2021;3(1):29-34.

Abstract:

Background: Multiple Myeloma (MM) is a
haematological cancer characterized by complications
of end-organ damage and subsequently high mortality.
Previously, there were few therapies available with
minimal survival benefit for most patients. Survival
was less than a year in many countries. The survival of
MM patients can range from 6 months to over 10 years,
with a median of 6 years, depending on stage of the
disease at diagnosis and prognostic factors. However,
with the advent of newer immune modulating agents
and novel therapies, there exists an opportunity to
improve the management of MM.
Objective: The purpose of this review is to discuss
the current chemotherapy and novel agents available
for treatment of Multiple Myeloma and highlight
emerging therapies in treatment of Multiple Myeloma,
some of which are now locally available in Kenya.
Data Sources: International Guidelines on Treatment
of Multiple Myeloma; Published articles from peerreviewed
journals; ESMO, NCCN guidelines on
Multiple Myeloma
Conclusion: New MM therapies have been shown to
improve progression-free survival and overall survival
of to upto 82% at four years. Some of these therapies
are now accessible locally through government
funding. In combination with a wholesome approach
which includes appropriate supportive care, there
exists an opportunity to improve the quality and
standard of care of MM patients in Kenya to replicate
the success of that in developed countries.
Key words: Multiple myeloma, Cancer

UoN Websites Search